Glycopyrronium tosylate

Chemical compound

Glycopyrronium tosylate, sold under the brand name Qbrexza among others, is a medication used for the treatment of primary axillary hyperhidrosis.^[1][2][3]

It was approved for medical use in the United States in June 2018,^[4] and in Japan in January 2022.^[5]

References

1. "Qbrexza- glycopyrronium cloth". DailyMed. 17 January 2022. Retrieved 2 November 2022.
2. Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, Tyring SK (March 2019). "Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis". Skin Therapy Letter. 24 (2): 1–3. PMID 30970203.
3. Lamb YN (November 2019). "Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use". Clinical Drug Investigation. 39 (11): 1141–1147. doi:10.1007/s40261-019-00853-x. PMC 6877702. PMID 31571127.
4. "Drug Approval Package: Qbrexza (glycopyrronium)". U.S. Food and Drug Administration (FDA). 20 November 2018. Retrieved 1 November 2022.
5. "Maruho Launches Primary Axillary Hyperhidrosis Treatment". Maruho. 23 May 2022. Retrieved 2 November 2022.